I do not think DS will jump to AD, he is targeting Parkinsonian diseases first. He is a very systematic person, and that is needed to get Phase 2 studies done. Now ATH as a business needs action. It needs to find a partner to get 434 approved in a few months and phase 3 for PD started. Depending on the partner an AD study needs to be planned and started. Masters, Bush, and Ayton are AD specialists and they are respected all over the world and have many connections in the pharma industry. Kempler with his old friends Masters etc will help Stamler to find a partner, I hope. On the American continent, DS has his friends, too. But action on every level needs to be taken. After the 201 results, this business cannot be a company with 11 full-time workers. Just too much work. Partner needed.
ATH Price at posting:
1.2¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)